Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials

Shamsher S Khan, Takefumi Komiya*

Abstract

Background: The exclusion of patients with autoimmune disease has been a topic of cancer immunotherapy trial. This study aims to find recent trends in exclusion of autoimmune disease. **Methods:** Using the website clinicaltrials. gov, we searched for clinical trials that were initiated in 2012 or later and enrolled patients with lung cancer who were treated with PD-1/PD-L1 therapy. Only trials including US locations were analyzed. **Results:** A total of 198 trials met screening criteria in this study. There were 68 trials which had complete exclusion of any autoimmune disease in patients. In addition, 13 trials excluded active autoimmune disease and 87 trials excluded active autoimmune disease requiring treatment. The remaining 37 trials had undefined exclusion. Studies that had larger enrollment of patients with autoimmune diseases were largely in industry. The complete exclusion of patients with autoimmune diseases has decreased recently. **Conclusion**: Exclusion of patients with active autoimmune diseases requiring treatment was one of the common exclusion criteria found. Strict exclusion of patients with autoimmune diseases has been decreasing over the years.

Keywords: Clinical trials- lung cancer- autoimmune disease- eligibility

Asian Pac J Cancer Prev, 24 (1), 331-336

Introduction

Lung Cancer is the third most common cancer in the United States (Centers for Disease Control and Prevention 2022). In 2022, there were approximately 236,000 cases of lung cancer in the United States (The American Cancer Society medical and editorial content team, 2022). In addition, more than 50% of lung cancer cases are diagnosed as stage IV (National Cancer Institute, 2022). Although there is a gradual increase in the 5-year survival rate for overall lung cancer cases, development of new systemic therapy is warranted to further improve the outcome (National Cancer Institute, 2022). Recently, installation of immunotherapy in lung cancer has dramatically changed the landscape in the management of advanced lung cancer (Fountzilas et al., 2022). The Food and Drug Administration (FDA) has approved anti-PD1/ PD-L1 agents for several disease settings in thoracic malignancy. Immunotherapy became an important part of systemic therapy; however, many trials do not enroll patients with autoimmune disease due to fear of flare-up secondary to immunotherapy.

By not including patients with autoimmune disease in cancer trials, it will negatively impact our understanding of how to treat those patients with cancer. Including more patients with autoimmune disease will help us to understand more about how to properly care for these patients as well as the relation between autoimmune disease and cancer. In a study done with 210,509 patients with lung cancer, 13.5% of those patients also had autoimmune disease (Khan et al., 2016). Increasing studies to help those in need of care with autoimmune disease and lung cancer will help make results easier to use across a larger variety of patients. If we always exclude them from pivotal clinical trials, the findings cannot be generalized in broad patient population.

To treat lung cancer more effectively, this study aims to find out the parameters of clinical trials regarding exclusion of patients with autoimmune disease. This study is also being conducted to see how this has been changing over the recent years.

Materials and Methods

To select trials which are relevant to the study, the website clinicaltrials.gov was used (NIH, 2022). Search criteria for clinical trials included study initiation year (2012 and later), diagnosis of lung cancer, use of a PD-1/PDL1 inhibitor, and study locations that included US institutions.

The data was analyzed based on several parameters. We obtained eligibility information regarding Eastern cooperative oncology group (ECOG) status, the sponsor type (industry, academic institution, or corporate group),

Division of Hematology/ Oncology, University at Buffalo, United States. *For Correspondence: takefumi@buffalo.edu

type of PD-1/PDL1 treatment, drug of PD-1/PDL1 (Pembrolizumab vs other drugs/cancer treatments), number of participants, stage (stage IV vs other stages), year of trial. Table 1 shows characteristics of selected trials.

The tables were made with categories pertaining to trial status, design, sponsor, location, treatments used, the year the study was initiated, as well as any specific anti-cancer drugs which were used. The tables made were also organized so that the degree of exclusion of patients with autoimmune diseases could be assessed. There was partial exclusion which was divided into two categories "A" and "B". "A" was excluding active autoimmune disease only if it required treatment. Complete exclusion was strict exclusion of any history of autoimmune disease. The proportion of patients which fit into any of these selections was analyzed. This is not a human-subject study but a study which reviews the publicly available existing clinical trials.

Statistical analyses were conducted according to chi-square tests. A two-sided p-value below 0.05 was considered as statistically significant.

Results

More than 50% of the trials are recruiting trials (Table 1). The phase I trials are the most prevalent (33%) compared to phase II and phase III trials (28% vs 11%). About 1% of the trials had an undefined phase. The location of the trials was also closely split with there being about 48% in the United States only and 52% of the trials in the United States and other countries. There were far more trials being conducted in industry making up 75% of the trials. The remaining sponsors were corporate groups and academic institutions (10% vs 15%). Most of the trials used a combination of PD-1/PD-L1 inhibitors with other agents (88%). There was about 7% of trials which used a PD-1/PD-L1 inhibitor with radiation and 4% used only PD-1/PD-L1 inhibitor. The remaining trial had an undefined treatment. The PD-1/PD-L1 inhibitor used was slightly more with Pembrolizumab at 55% and 45% for other drugs/cancer treatments. Most trials were conducted with 101-1000 participants at 59%. Non-small cell lung cancer was the most prevalent disease being studied in clinical trials making up 51% of all clinical trials in the study. Lung cancer and any other cancer was the next largest at 43%. The stage IV lung cancer made up most trials at 94%. The ECOG score for most trials was 0-1 since they made up 74% of all trials.

In Table 1, the type of exclusion for each category is also shown along with its percentage of the total. Exclusion of autoimmune diseases which requires systemic treatment as well as strict exclusion are the most common in all the categories. Exclusion of only active autoimmune diseases is the least common among each category.

In Table 2, there are 11 categories from which chi square calculations were performed. Strict exclusion is less frequent in phase II/III and III trials and pembrolizumab trials than other trials (both p<0.001). Partially allowing patients with autoimmune disease is less frequent in trials with stage IV (45%) than those with others (82%) (p=0.033). There is no significant association between the exclusion type and other study characteristics.

The Table 3 and Figure 1 show a trend of different exclusion types over a period of years from 2012 to 2022. Trials in more recent years have allowed more patients with autoimmune diseases than previously.

Discussion

Historically, many of the trials in cancer immunotherapy excluded patients with active or history of autoimmune diseases. In our study, more than 60% of the trials at least conditionally allowed patients with autoimmune disease. Over the years from 2012 to 2022 the number of trials with strict exclusion of autoimmune disease has been decreasing. This may suggest that the treating oncologists are now used to and more capable of managing patients with autoimmune disease.

Recent studies reported that cancer patients with autoimmune disease can be safely treated with modern immunotherapy. Immune checkpoint inhibitors were found to be suitable for active or inactive autoimmune



Figure 1. Trend in Exclusion

Table 1. The Study Characteristics and Exclusion Status

Characteristics	Strict Exclusion,	Partial A	Partial B	Other, $N(\theta_{1})$	Total,
	IN (70)	Excluding Active Autoimmune Disease, N (%)	Excluding Autoimmune Disease which requires systemic treatment, N (%)	IN (70)	IN (70)
Total	68 (34)	13 (7)	80 (40)	37 (19)	198 (100)
Trial Type				• (••)	
Recruiting	28 (28)	6 (6)	41 (41)	26 (26)	101 (100)
Active, not recruiting	19 (33)	4 (7)	28 (49)	6 (11)	57 (100)
Completed	21 (53)	3 (8)	11 (28)	5 (13)	40 (100)
Trial Phase					
Phase 1/2/1 and 2	66 (38)	13 (8)	62 (36)	31 (18)	172 (100)
Phase 2 and 3/3	2 (8)	0 (0)	18 (75)	4 (17)	24 (100)
Phase NA	0 (0)	0 (0)	0 (0)	2 (100)	2 (100)
Location					
United States only	38 (40)	6 (6)	33 (35)	18 (19)	95 (100)
United States and other countries	30 (29)	7 (7)	47 (46)	19 (18)	103 (100)
Sponsor Type					
Industry	46 (31)	9 (6)	62 (42)	32 (22)	149 (100)
Corporate Group	7 (37)	4 (21)	4 (21)	4 (21)	19 (100)
Academic Institution	15 (50)	0 (0)	14 (47)	1 (3)	30 (100)
Treatment Type					
Combination of PD-1/PD-L1 with other agents	58 (33)	12 (7)	69 (39)	36 (21)	175 (100)
PD-1/PD-L1 with Radiation	6 (43)	0 (0)	7 (50)	1 (7)	14 (100)
PD-1/PD-L1 only	4 (50)	0 (0)	4 (50)	0 (0)	8 (100)
Treatment Type Not Available (Undefined)	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)
PD-1/PD-L1 Agent Used					
Including Pembrolizumab	24 (22)	4 (4)	57 (53)	23 (21)	108 (100)
Other drugs/cancer treatments	44 (49)	9 (10)	23 (26)	14 (16)	90 (100)
Participants Involved (Sample Size)					
0-20 Participants	8 (47)	1 (6)	6 (35)	2 (12)	17 (100)
21-100 Participants	28 (48)	6 (10)	22 (37)	3 (5)	59 (100)
101-1000 Participants	31 (27)	6 (5)	49 (42)	31 (27)	117 (100)
1001-2000 Participants	1 (20)	0 (0)	3 (60)	1 (20)	5 (100)
Type of Lung Cancer					
Non-small cell lung Cancer	32 (32)	5 (5)	49 (49)	15 (15)	101 (100)
Small Cell lung Cancer	2 (20)	1 (10)	7 (70)	0 (0)	10 (100)
Both Non-small cell lung cancer and Small Cell lung Cancer	1 (100)	0 (0)	0 (0)	0 (0)	1 (100)
Lung Cancer and any other type of Cancer	33 (38)	7 (8)	24 (28)	22 (26)	86 (100)
Stage of Lung Cancer					
Including Stage 4	67 (36)	13 (7)	71 (38)	36 (19)	187 (100)
Other Stages	1 (9)	0 (0)	9 (82)	1 (9)	11 (100)
ECOG					
0-1	52 (36)	10 (7)	62 (43)	22 (15)	146 (100)
Including 2	12 (35)	2 (6)	12 (35)	8 (24)	34 (100)
Not Available	4 (22)	1 (6)	6 (33)	7 (39)	18 (100)

Shamsher S Khan and Takefumi Komiya

Table 2. Association between the Characteristics and Exclusion Criteria: Consolidated Analysis

Exclusion, N (%) Partially, N (%) N (%) N (%) Total 68 (34) 93 (47) 37 (19) 198 (100) Trial Type 0.055 0.051 0.051 Recruiting 28 (28) 47 (47) 52 (50) 101 (100) Completed 21 (33) 32 (56) 6 (11) 57 (100) Completed 21 (33) 14 (35) 5 (13) 40 (100) Trial Phase p=0.001 Phase I, II, I/II 66 (38) 75 (44) 31 (18) 172 (100) Phase I, II, I/II 2 (8) 18 (75) 4 (17) 24 (100) Phase NA 0 (0) 0 (0) 2 (100) 0.08 United States only 38 (40) 39 (41) 18 (19) 95 (100) United States only 38 (40) 39 (41) 18 (19) 96 (100) Comporatic Group 7 (37) 8 (42) 4 (21) 19 (100) Comporatic Group 7 (37) 8 (42) 1 (20) 100 PD-I/PD-L1 with other agents 58 (33) 81 (46)<		Strict	Allowed	Other	Total	p Value
Total 68 (34) 93 (47) 37 (19) 198 (100) Trial Type 0.055 Recruiting 28 (28) 47 (47) 26 (26) 101 (100) Active, not recruiting 19 (33) 32 (56) 6 (11) 57 (100) Completed 21 (3) 14 (35) 5 (13) 40 (10) Trial Phase p=0.001 Phase I, II, J/II 66 (38) 75 (44) 31 (18) 172 (100) Phase I, II, J/II 6 (63) 75 (44) 31 (18) 95 (00) Cancian 0 (0) 0 (0) 2 (100) 2 (100) Location 0 (0) 0 (10) 95 (00) 0 (10) United States only 38 (40) 39 (41) 18 (19) 95 (00) Industry 46 (31) 71 (48) 32 (22) 149 (100) Corborate Group 7 (77) 8 (42) 4 (21) 19 (100) Cardemic Institution 15 (50) 11 (47) 13 (30) 000 Treatment Type 7 (27) 8 (42) 6 (21) </th <th></th> <th>Exclusion, N (%)</th> <th>Partially, N (%)</th> <th>N (%)</th> <th>N (%)</th> <th></th>		Exclusion, N (%)	Partially, N (%)	N (%)	N (%)	
Trial Type 0.055 Recruining 28 (28) 47 (47) 26 (26) 01 (10) Active, for tecruiting 21 (33) 41 (35) 5 (13) 40 (100) Trial Phase	Total	68 (34)	93 (47)	37 (19)	198 (100)	
Recruiting 28 (23) 47 (47) 26 (26) 101 (100) Active, not recruiting 19 (33) 32 (56) 6 (11) 57 (100) Completed 21 (53) 14 (35) 5 (1) 40 (100) Trial Phase p=0.001 \$\prop_0001 \$\prop_0	Trial Type					0.055
Active, not recruiting 19 (33) 32 (56) 6 (11) 57 (100) Completed 21 (3) 14 (55) 5 (13) 40 (100) Piase I, II, VII 66 (38) 75 (44) 31 (18) 172 (100) Phase I, II, VII 6 (38) 75 (44) 31 (18) 172 (100) Phase NA 0 (0) 0 (0) 2 (100) 2 (100) Cocation 0.08 39 (41) 18 (19) 95 (100) United States and other countries 30 (29) 54 (52) 19 (18) 0 (10) Sponsor Type 0.449 13 (13) 30 (100) 46 (31) 71 (48) 32 (22) 149 (100) Academic Institution 15 (50) 14 (47) 13 (13) 100 (100) Academic Institution 15 (50) 14 (47) 13 (13) 100 (100) PD-1/PD-L1 with other agents 5 8 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 with Adataion 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (41) <	Recruiting	28 (28)	47 (47)	26 (26)	101 (100)	
Completed 21 (53) 14 (35) 5 (13) 40 (100) Trial Prase p<0.01	Active, not recruiting	19 (33)	32 (56)	6 (11)	57 (100)	
Trial Phase ps0.01 Phase I, II, II,II 66 (38) 75 (44) 31 (18) 172 (10) Phase I, II, II,II 2 (8) 18 (75) 4 (17) 24 (100) Phase IA, II, II,II 2 (8) 18 (75) 4 (17) 24 (100) Location 0 (0) 30 (20) 35 (25) 19 (18) 103 (100) Location 6 (31) 71 (48) 32 (22) 149 (100) Coporate Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 6 (33) 7 (14) 36 (21) 175 (100) Treatment Type 0 (0) 14 (17) 14 (100) 0 PD-1/PD-1.1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-1.1 only 6 (43) 7 (50) 1 (17) 14 (100) 0 PD-1/PD-1.1 only 6 (43) 7 (61) 20 (13) 10 (100) 0 0 Including Pembrolizamab 24 (29) 32 (35) 14 (16) 9 (100) 0 0 <t< td=""><td>Completed</td><td>21 (53)</td><td>14 (35)</td><td>5 (13)</td><td>40 (100)</td><td></td></t<>	Completed	21 (53)	14 (35)	5 (13)	40 (100)	
Phase I, II, I/II 66 (38) 75 (44) 31 (18) 172 (100) Phase I/III, III 2 (8) 18 (75) 4 (17) 24 (100) Phase NA 0 (0) 0 (0) 2 (100) 2 (100) Location 0.08 39 (41) 18 (19) 95 (100) United States only 38 (40) 39 (41) 18 (19) 95 (100) Sponsor Type 66 (31) 71 (48) 32 (22) 149 (100) Corporate Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 15 (50) 14 (47) 1 (3) 30 (100) Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 agent Used 64 (33) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 agent Used 64 (49) 32 (36) 14 (16) 90 (100) PD-1/PD-L1 agent Used pe-0.01 1 (100) 0 (0) 1 (100) Other drugs/cancer treatments 44 (49) 32 (36) 14 (16) 90 (100) <td< td=""><td>Trial Phase</td><td></td><td></td><td></td><td></td><td>p<0.001</td></td<>	Trial Phase					p<0.001
Phase NA 2 (8) 18 (75) 4 (17) 24 (100) Phase NA 0 (0) 0 (0) 2 (100) 2 (100) Location 0.08 0 (0) 2 (100) 2 (100) Location 0.08 39 (41) 18 (19) 95 (100) United States and other countries 30 (29) 54 (52) 19 (18) 103 (100) Sponsor Type	Phase I, II, I/II	66 (38)	75 (44)	31 (18)	172 (100)	
Phase NA 0 (0) 0 (0) 2 (100) 2 (100) Location 0.08 United States and other countries 30 (20) 54 (52) 19 (18) 03 (10) Sponsor Type 0.49 Industry 46 (31) 71 (48) 32 (22) 149 (100) Corporate Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 15 (5) 14 (10) 90 (10) 00 Poor at Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 15 (5) 17 (7) 14 (100) 90 (10) PD-1/PD-L1 with Relation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Relation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Relation 6 (43) 7 (50) 10 (7) 14 (100) PD-1/PD-L1 Agent Used p<0.001	Phase II/III, III	2 (8)	18 (75)	4 (17)	24 (100)	
Location 0.08 United States only 38 (40) 39 (41) 18 (19) 95 (100) Lindust States and other countries 30 (40) 19 (18) 103 (100) Sponsor Type 0.449 Industry 46 (31) 71 (48) 32 (22) 149 (100) Academic Institution 15 (50) 14 (47) 1 (3) 30 (100) Tearmer Type 0.735 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 only 4 (50) 4 (50) 0 (0) 8 (100) Treatment Type Not Available (Indefined) 0 (0) 1 (100) 0 (0) 1 (100) PD-1/PD-L1 with Radiation 6 (42) 2 (157) 108 (100) 0 (100) PD-1/PD-L1 Agent Used p<0.001	Phase NA	0 (0)	0 (0)	2 (100)	2 (100)	
Inited States only 38 (40) 39 (41) 18 (19) 95 (100) United States and other countries 30 (29) 54 (52) 19 (18) 103 (100) Sponsor Type 0.449 Industry 46 (31) 71 (48) 32 (22) 149 (100) Corporte Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 15 (50) 14 (47) 1 (3) 30 (100) Treatment Type 0.795 0.795 0.795 Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 14 (100) PD-1/PD-L1 with Radiation 6 (33) 7 (50) 10 (100) 10 (0) 10 (0) PD-1/PD-L1 with Radiation 6 (30) 7 (50) 13 (100) 10 (0) PD-1/PD-L1 Agent Used $y = 0.001$ 10 (00) 0 (0) 10 (00) PD-1/PD-L1 Agent Used 24 (22) 61 (57) 23 (21) 108 (100) Participants Involved (Sample Size) 0.264 3 (5) 59 (100) 101-1000 31 (27) 55 (Location					0.08
United States and other countries 30 (29) 54 (52) 19 (18) 103 (100) Sponsor Type 0.449 Industry 46 (31) 71 (48) 32 (22) 149 (100) Corporate Group 7 (37) 8 (42) 42 (1) 19 (100) Academic Institution 15 (50) 14 (47) 1 (3) (30 (100) Treatment Type 0.795 0.757 (100) 0.795 Combination of PD-1/PD-L1 with dufter agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 only 4 (50) 4 (50) 0 (0) 8 (100) 1000 PD-1/PD-L1 only 4 (50) 4 (40) 32 (21) 108 (100) 1000 Other drugs/cancer treatments 24 (22) 61 (57) 23 (21) 108 (100) 1000 Other drugs/cancer treatments 44 (49) 32 (36) 14 (16) 90 (100) 101 Other drugs/cancer treatments 48 (47) 7 (41) 2 (12) 17 (100) 101 Other drugs/cancer treatments 28 (47) 7 (41) 2 (12) 17 (1	United States only	38 (40)	39 (41)	18 (19)	95 (100)	
Sponsor Type 0.449 Industry 46 (31) 71 (48) 32 (22) 149 (100) Corporate Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 16 (30) 14 (47) 13 (30) (100) 0.00 Treatment Type 0.795 0.795 0.795 0.795 Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 only 4 (60) 4 (60) 0 (0) 8 (100) 0.00 100 PD-1/PD-L1 only 4 (60) 1 (100) 0 (0) 100 0.00 0.00 PD-1/PD-L1 only 4 (40) 32 (36) 14 (16) 90 (100) 0.00	United States and other countries	30 (29)	54 (52)	19 (18)	103 (100)	
Industry46 (31)71 (48) 32 (22)149 (100)Corporate Group7 (37)8 (42)4 (21)19 (100)Academic Institution15 (50)14 (47)1 (3)30 (100)Treatment Type 0.795 Combination of PD-1/PD-L1 with other agents58 (33)81 (46)36 (21)175 (100)PD-1/PD-L1 with adiation6 (43)7 (50)1 (7)14 (100)PD-1/PD-L1 vith Radiation6 (43)7 (50)0 (0)8 (100)Treatment Type Not Available (Undefined)0 (0)1 (100)0 (0)1 (100)PD-1/PD-L1 Agent Used $p < 0.001$ 100 (00)100 (00)Including Pembrolizumab24 (22)61 (57)23 (21)108 (100)Other drugs/cancer treatments24 (49)32 (5)17 (100)2640-208 (47)7 (41)2 (12)17 (100)21 (100)21-10028 (48)28 (48)3 (5)59 (100)000101-100031 (27)55 (47)31 (27)117 (100)101-20001 (20)30 (36)1 (20)50 (100)Type of Lung Cancer32 (32)54 (54)56 (15)101 (100)Small Cell lung Cancer33 (38)31 (35)22 (26)86 (100)Small Cell lung Cancer33 (38)31 (35)22 (26)86 (100)Concer33 (38)31 (36)22 (26)86 (100)Small Cell lung Cancer33 (38)31 (36)22 (26)86 (100)Concer1 (100)0 (0)	Sponsor Type					0.449
Corporate Group 7 (37) 8 (42) 4 (21) 19 (100) Academic Institution 15 (50) 14 (47) 1 (3) 30 (100) Treatment Type 0.795 Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 only 4 (50) 0 (0) 8 (100) 1000 Treatment Type Not Available (Undefined) 0 (0) 1 (100) 0 (0) 1 (100) Other drugs/cancer treatments 24 (22) 61 (57) 23 (21) 108 (100) Other drugs/cancer treatments 24 (22) 61 (57) 23 (21) 17 (100) 21-100 28 (48) 3 (5) 59 (100) 101 101 101-1000 13 (27) 55 (47) 31 (27) 17 (100) 101 101-1000 12 (20) 3 (60) 12 (20) 5 (10) 10 (100)	Industry	46 (31)	71 (48)	32 (22)	149 (100)	
Academic Institution 15 (50) 14 (47) 1 (3) 30 (100) Treatment Type 0.795 Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 only 4 (50) 4 (50) 0 (0) 8 (100) Treatment Type Not Available (Undefined) 0 (0) 1 (100) 0 (0) 1 (100) PD-1/PD-L1 Agent Used $p<0.001$	Corporate Group	7 (37)	8 (42)	4 (21)	19 (100)	
Treatment Type 0.795 Combination of PD-1/PD-L1 with other agents 58 (33) 81 (46) 36 (21) 175 (100) PD-1/PD-L1 with Radiation 6 (43) 7 (50) 1 (7) 14 (100) PD-1/PD-L1 only 4 (50) 4 (50) 0 (0) 8 (100) Treatment Type Not Available (Undefined) 0 (0) 1 (100) 0 (0) 1 (100) PD-1/PD-L1 Agent Used reatments 24 (22) 61 (57) 23 (21) 108 (100) Other drugs/cancer treatments 44 (42) 61 (57) 23 (21) 108 (100) 0.264 Other drugs/cancer treatments 44 (42) 61 (57) 23 (21) 17 (100) 0.264 Participants Involved (Sample Size) 0.264 3 (5) 59 (100) 0.264 0-20 8 (47) 7 (41) 2 (12) 17 (100) 0.264 101-1000 13 (27) 55 (47) 31 (27) 51 (00) 0.087 Non-small cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) 0.087 Stage of Lung Cancer 1 (20) 3 (38) 31 (36) 22 (26) 8 (100) 0.033 <td>Academic Institution</td> <td>15 (50)</td> <td>14 (47)</td> <td>1 (3)</td> <td>30 (100)</td> <td></td>	Academic Institution	15 (50)	14 (47)	1 (3)	30 (100)	
$\begin{array}{ c c c c } Combination of PD-1/PD-L1 with other agents $$ 8(33) $$ 1(46) $$ 36(21) $$ 175(100) $$ 107 $$ 14(100) $$ PD-1/PD-L1 with Radiation $$ 6(43) $$ 7(50) $$ 1(7) $$ 14(100) $$ PD-1/PD-L1 only $$ 4(50) $$ 4(50) $$ 0(0) $$ 1(100) $$ 0(0) $$ 1(100) $$ 0(0) $$ 1(100) $$ PD-1/PD-L1 Agent Used $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$$	Treatment Type					0.795
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Combination of PD-1/PD-L1 with other agents	58 (33)	81 (46)	36 (21)	175 (100)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	PD-1/PD-L1 with Radiation	6 (43)	7 (50)	1 (7)	14 (100)	
Treatment Type Not Available (Undefined) 0 (0) 1 (100) 0 (0) 1 (100) $p < 0.01$ PD-1/PD-L1 Agent Used $p < 0.01$ <	PD-1/PD-L1 only	4 (50)	4 (50)	0 (0)	8 (100)	
PD-1/PD-11 Agent Used p<0.01	Treatment Type Not Available (Undefined)	0 (0)	1 (100)	0 (0)	1 (100)	
Including Pembrolizumab 24 (22) 61 (57) 23 (21) 108 (100) Other drugs/cancer treatments 44 (49) 32 (36) 14 (16) 90 (100) Participants Involved (Sample Size) 0.264 0.20 17 (100) 17 (100) 21-100 28 (48) 28 (48) 3 (5) 59 (100) 101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Small Cell lung Cancer 3 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 1 (100) Cancer 33 (38) 31 (36) 22 (26) 86 (100) Cancer 57 (36) 84 (45) 36 (19) 187 (100) Cancer 1 (9) 9 (82) 1 (9) 11 (100) Cancer 52 (36) 72 (49) 22 (15) 146 (100) Including Stage IV 67 (36) <td>PD-1/PD-L1 Agent Used</td> <td></td> <td></td> <td></td> <td></td> <td>p<0.001</td>	PD-1/PD-L1 Agent Used					p<0.001
Other drugs/cancer treatments 44 (49) 32 (36) 14 (16) 90 (100) Participants Involved (Sample Size) 0.264 0-20 8 (47) 7 (41) 2 (12) 17 (100) 21-100 28 (48) 28 (48) 3 (5) 59 (100) 101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 1 (100) 0 (0) Cancer 2 200 8 (445) 36 (19) 187 (100) Cancer 1 (9) 9 (82) 1 (9) 11 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) 0.511	Including Pembrolizumab	24 (22)	61 (57)	23 (21)	108 (100)	
Participants Involved (Sample Size) 0.264 0-20 8 (47) 7 (41) 2 (12) 17 (100) 21-100 28 (48) 28 (48) 3 (5) 59 (100) 101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 22 (20) 8 (80) 0 (0) 10 (100) Small Cell lung Cancer 23 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 2 200 8 4 (45) 36 (19) 187 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 0.011 <	Other drugs/cancer treatments	44 (49)	32 (36)	14 (16)	90 (100)	
0-20 8 (47) 7 (41) 2 (12) 17 (100) 21-100 28 (48) 28 (48) 3 (5) 59 (100) 101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 2 7 (36) 84 (45) 36 (19) 187 (100) Other Stages of Lung Cancer 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.1 1 (9) 9 (82) 1 (9) 11 (100) ECOG 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not	Participants Involved (Sample Size)					0.264
21-100 28 (48) 28 (48) 3 (5) 59 (100) 101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 101 100 0 (0) 1 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	0-20	8 (47)	7 (41)	2 (12)	17 (100)	
101-1000 31 (27) 55 (47) 31 (27) 117 (100) 1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 1 100 0 (0) 1 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	21-100	28 (48)	28 (48)	3 (5)	59 (100)	
1001-2000 1 (20) 3 (60) 1 (20) 5 (100) Type of Lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 1 (100) 0 (0) 0 (0) 1 (100) 0.033 Stage of Lung Cancer 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.051 0.851 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	101-1000	31 (27)	55 (47)	31 (27)	117 (100)	
Type of Lung Cancer 0.087 Non-small cell lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 0.033 10 (100) 0 (0) 1 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.1 (100) 0.851 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	1001-2000	1 (20)	3 (60)	1 (20)	5 (100)	
Non-small cell lung Cancer 32 (32) 54 (54) 15 (15) 101 (100) Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 0.033 11 (100) 0 (0) 187 (100) 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Type of Lung Cancer					0.087
Small Cell lung Cancer 2 (20) 8 (80) 0 (0) 10 (100) Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Cancer 0.033 Stage of Lung Cancer 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Non-small cell lung Cancer	32 (32)	54 (54)	15 (15)	101 (100)	
Lung Cancer and any other type of Cancer 33 (38) 31 (36) 22 (26) 86 (100) Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 0 (0) 1 (100) Stage of Lung Cancer 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Small Cell lung Cancer	2 (20)	8 (80)	0 (0)	10 (100)	
Both Non-small cell lung cancer and Small Cell lung 1 (100) 0 (0) 1 (100) Cancer Stage of Lung Cancer 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Lung Cancer and any other type of Cancer	33 (38)	31 (36)	22 (26)	86 (100)	
Stage of Lung Cancer 0.033 Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Both Non-small cell lung cancer and Small Cell lung Cancer	1 (100)	0 (0)	0 (0)	1 (100)	
Including Stage IV 67 (36) 84 (45) 36 (19) 187 (100) Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Stage of Lung Cancer					0.033
Other Stages 1 (9) 9 (82) 1 (9) 11 (100) ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Including Stage IV	67 (36)	84 (45)	36 (19)	187 (100)	
ECOG 0.851 0-1 52 (36) 72 (49) 22 (15) 146 (100) Including 2 12 (35) 14 (41) 8 (24) 34 (100) Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Other Stages	1 (9)	9 (82)	1 (9)	11 (100)	
0-152 (36)72 (49)22 (15)146 (100)Including 212 (35)14 (41)8 (24)34 (100)Not Available4 (22)7 (39)7 (39)18 (100)	ECOG					0.851
Including 212 (35)14 (41)8 (24)34 (100)Not Available4 (22)7 (39)7 (39)18 (100)	0-1	52 (36)	72 (49)	22 (15)	146 (100)	
Not Available 4 (22) 7 (39) 7 (39) 18 (100)	Including 2	12 (35)	14 (41)	8 (24)	34 (100)	
	Not Available	4 (22)	7 (39)	7 (39)	18 (100)	

Table 3. Trends in Exclusion Status Since 2012

Year	Strict Exclusion (%)	Allowed Partially (%)	Other (%)	Total (%)	p Value*
Total	68 (34)	93 (50)	37 (19)	198 (100)	p<0.001
2012-2016	17 (47)	14 (38)	5 (14)	36 (100)	
2017-2018	24 (36)	37 (56)	5 (8)	66 (100)	
2019-2020	21 (34)	28 (46)	12 (20)	61 (100)	
2021-2022	6 (17)	14 (40)	15 (43)	35 (100)	

*, the trend among study periods.

disease (Antonuzzo et al., 2020). Another study also found that involving patients with autoimmune disease with immune checkpoint inhibitors would not only be safe but also increase the efficacy of these treatments in both active and inactive autoimmune disease while having similar results and tolerability. (Boland et al., 2020; Florou et al., 2021; Rakshit et al., 2020; Zakharian et al., 2021). Other studies also suggest excluding treatment for patients with autoimmune diseases may affect their health from which no alternative treatment is available (Duma et al., 2019; Pantuck et al., 2019). It has been suggested that patients with autoimmune diseases can participate in clinical trials with immune checkpoint inhibitors if the managing physicians monitor the effects that the treatment has on the patient (Pantuck et al., 2019). These observations and considerations are in line with the recent decrease in strict exclusion of autoimmune disease from lung cancer clinical trials.

There are some limitations to this study. Study locations and primary cancer site must have included US and lung, respectively. The use of clinicaltrials. gov to screen trials may have limited information and lead to some biases. Trials that have discontinued were not included. Nevertheless, our findings suggest that researchers became more permissive to enrolling patients with autoimmune disease.

In conclusion, our retrospective study using clinical trial registry suggests that patients with lung cancer and autoimmune disease are increasing allowed to participate in immunotherapy trials. This observation is supported by several studies that immunotherapy seems well-tolerated in those individuals. Further investigations to validate the findings are warranted.

Author Contribution Statement

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Shamsher S. Khan. The first draft of the manuscript was written by Shamsher S. Khan and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Authors thank Dr. Roberto Pili for administrative support.

Ethical Approval

This is not a human-subject study but is a study which reviews publicly available clinical trials. The article does not contain any studies performed by the authors that were with human participants or animals.

References

Antonuzzo A, Calabrò F, Quaglino P, et al (2020). Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. Oncologist, 25, e946-e4.

- Boland P, Pavlick AC, Weber J, et al (2020). Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. *J Immunother Cancer*, **8**, e000356.
- Centers for Disease Control and Prevention (2022). Lung Cancer Statistics Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. Available from: https:// www.cdc.gov/cancer/lung/statistics/index.htm. Accessed 21 August 2022.
- Coureau M, Meert AP, Berghmans T, et al (2020). Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders. *Front Med*, **7**, 137.
- Duma N, Kothadia SM, Azam TU, et al (2019). Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. *Oncologist*, **24**, 96-102.
- Florou V, Puri S, Garrido-Laguna I, et al (2021). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. *Ann Transl Med*, **9**, 1035.
- Fountzilas E, Lampaki S, Koliou GA, et al (2022). Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. *Cancer Immunol Immunother*, **71**, 327-37.
- Haanen J, Ernstoff MS, Wang Y, et al (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. *Ann Oncol*, **31**, 724-44.
- Kennedy LC, Bhatia S, Thompson JA, et al (2019). Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. J Natl Compr Canc Netw, 17, 750-7.
- Khan SA, Pruitt SL, Xuan L, et al (2016). Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. *JAMA Oncol*, 2, 1507-8.
- Khan SA, Pruitt SL, Xuan L, et al (2018). How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. *Lung Cancer*, **115**, 97-102.
- Leonardi GC, Gainor JF, Altan M, et al (2018). Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. *J Clin Oncol*, **36**, 1905-12.
- National Cancer Institute (2022). Cancer Stat Facts: Lung and Bronchus Cancer National Cancer Institute: National Cancer Institute, Surveillance, Epidemiology, and End Results Program; Available from: https://seer.cancer.gov/statfacts/ html/lungb.html. Accessed 21 August 2022.
- NIH US National Library of Medicine (2022). ClinicalTrials. gov. Available from: https://clinicaltrials.gov/. Accessed 21 August 2022.
- Pantuck M, McDermott D, Drakaki A (2019). To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. *Cancer*, **125**, 3506-13.
- Rakshit S, Molina JR (2020). Immunotherapy in patients with autoimmune disease. *J Thorac Dis*, **12**, 7032-8.
- Tang H, Zhou J, Bai C (2021). The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. *Front Oncol*, **11**, 625872.
- The American Cancer Society medical and editorial content team (2022). Key Statistics for Lung Cancer American Cancer Society: American Cancer Society. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics. html. Accessed 21 August 2022.
- Zakharian L, Lee L (2021). Successful Use of Immunotherapy in a Patient with Metastatic Squamous Cell Lung Cancer

Shamsher S Khan and Takefumi Komiya

and Underlying Autoimmune Disease. *Cureus*, **13**, e15918. Zhang K, Kong X, Li Y, et al (2022). PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. *Front Pharmacol*, **13**, 854967.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.